These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10071972)

  • 1. The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer.
    Bennett CL; Stinson TJ; Yang T; Lurain JR
    Semin Oncol; 1999 Feb; 26(1 Suppl 1):40-5. PubMed ID: 10071972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients.
    Stinson TJ; Calhoun E; Yang T; Lurain JR; Bennett CL
    Cancer Invest; 1999; 17(8):559-65. PubMed ID: 10592762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
    Navarro RP; Morrow T; Baran R
    Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
    Orr JW; Orr P; Kern DH
    Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
    Moreno-Aspitia A; Perez EA
    Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reimbursement: current status and future outlook.
    Bailes JS
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):118-22. PubMed ID: 8091237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long time therapy with topotecan in patients with recurrence of ovarian carcinoma.
    Möbus V; Pfaff PN; Volm T; Kreienberg R; Kaubitzsch S
    Anticancer Res; 2001; 21(5):3551-6. PubMed ID: 11848522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpreting the economic literature in oncology.
    Grusenmeyer PA; Wong YN
    J Clin Oncol; 2007 Jan; 25(2):196-202. PubMed ID: 17210940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
    Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
    De Placido S; Scambia G; Di Vagno G; Naglieri E; Lombardi AV; Biamonte R; Marinaccio M; Cartenì G; Manzione L; Febbraro A; De Matteis A; Gasparini G; Valerio MR; Danese S; Perrone F; Lauria R; De Laurentiis M; Greggi S; Gallo C; Pignata S
    J Clin Oncol; 2004 Jul; 22(13):2635-42. PubMed ID: 15226331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries.
    Gross DJ; Alecxih L; Gibson MJ; Corea J; Caplan C; Brangan N
    Health Serv Res; 1999 Apr; 34(1 Pt 2):241-54. PubMed ID: 10199672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.
    Hensley ML; Hoppe B; Leon L; Sabbatini P; Aghajanian C; Chi D; Spriggs DR
    Gynecol Oncol; 2001 Sep; 82(3):464-9. PubMed ID: 11520141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enrollment of older persons in cancer trials after the medicare reimbursement policy change.
    Gross CP; Wong N; Dubin JA; Mayne ST; Krumholz HM
    Arch Intern Med; 2005 Jul; 165(13):1514-20. PubMed ID: 16009867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
    Sood AK; Lush R; Geisler JP; Shahin MS; Sanders L; Sullivan D; Buller RE; Sorosky JI
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6080-5. PubMed ID: 15447993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of care for elderly cancer patients in the United States.
    Yabroff KR; Lamont EB; Mariotto A; Warren JL; Topor M; Meekins A; Brown ML
    J Natl Cancer Inst; 2008 May; 100(9):630-41. PubMed ID: 18445825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.